1-(1,3-苯并二氧-5-基)哌啶-4-酮 | 267428-44-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 1-(1,3-苯并二氧-5-基)哌啶-4-酮
• 中文别名: 1-(1,3-苯并二唑-5-基)-4-哌啶基酮
• 英文名称: 1-(3,4-methylenedioxyphenyl)-4-piperidone
• 英文别名: 1-(1,3-Benzodioxol-5-yl)piperidin-4-one
• CAS: 267428-44-4
• 化学式: C₁₂H₁₃NO₃
• mdl: MFCD02090100
• 分子量: 219.24
• InChiKey: YUEKZMYUVRHVQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1-(1,3-苯并二氧-5-基)哌啶-4-酮 在 盐酸羟胺 、 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 以67%的产率得到1-(3,4-methylenedioxyphenyl)-4-piperidone oxime
  参考文献：
  名称：

  Stepwise versus Direct Long-Range Charge Separation in Molecular Triads

  摘要：

  Trifunctional electron donor-donor-acceptor molecules are described in which photoinduced charge separation, D-2-D-1-A* --> D-2-D-1(+)-A(-), is followed by a charge migration step D-2-D-1(+)-A(-) (CS1) --> D-2(+)-D-1-A- (CS2), leading to a relatively long-lived charge-separated state. The rate of the charge migration process could be determined in a range of solvents of low polarity. In benzene and dioxane, reversibility of the process allowed the determination of the free energy difference between CS1 and CS2. The relative energy of the CS2 state is much lower than expected from simple electrostatic models. An increase of the charge migration rate was found with increasing solvent polarity within a series of alkyl ethers or alkyl acetates. However, an apparent preferential stabilization of the CS1 state in acetates relative to ethers leads to discontinuities in the solvatochromic shift behavior of the CT fluorescence from the CS1 state, and in the increase of the charge migration rate as a function of dielectric constant. In a reference compound lacking the intermediate redox unit, direct long-range charge separation yielding a D-2(+)-bridge-A(-) charge-separated state can occur, but the yield is significantly lower than in the triads.

  DOI：

  10.1021/ja983716r
• 作为产物：
  描述：

  1,5-二氯-3-戊酮 、 3,4-亚甲二氧基苯胺 在 sodium carbonate 作用下， 以 甲醇 为溶剂， 以79%的产率得到1-(1,3-苯并二氧-5-基)哌啶-4-酮
  参考文献：
  名称：

  Stepwise versus Direct Long-Range Charge Separation in Molecular Triads

  摘要：

  Trifunctional electron donor-donor-acceptor molecules are described in which photoinduced charge separation, D-2-D-1-A* --> D-2-D-1(+)-A(-), is followed by a charge migration step D-2-D-1(+)-A(-) (CS1) --> D-2(+)-D-1-A- (CS2), leading to a relatively long-lived charge-separated state. The rate of the charge migration process could be determined in a range of solvents of low polarity. In benzene and dioxane, reversibility of the process allowed the determination of the free energy difference between CS1 and CS2. The relative energy of the CS2 state is much lower than expected from simple electrostatic models. An increase of the charge migration rate was found with increasing solvent polarity within a series of alkyl ethers or alkyl acetates. However, an apparent preferential stabilization of the CS1 state in acetates relative to ethers leads to discontinuities in the solvatochromic shift behavior of the CT fluorescence from the CS1 state, and in the increase of the charge migration rate as a function of dielectric constant. In a reference compound lacking the intermediate redox unit, direct long-range charge separation yielding a D-2(+)-bridge-A(-) charge-separated state can occur, but the yield is significantly lower than in the triads.

  DOI：

  10.1021/ja983716r

文献信息

• Compounds useful as antagonists of CCR2
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US08067457B2

  公开（公告）日：2011-11-29

  The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.

  本发明提供了通式I的化合物：或其药学上可接受的盐，其中X，n，Y和R1在此总体上和子集中被定义。本发明的化合物是CCR2的抑制剂，因此可用于治疗各种炎症、过敏和自身免疫性疾病、疾病或病况。
• COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2
  申请人：Ghosh Shomir

  公开号：US20120214807A1

  公开（公告）日：2012-08-23

  The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R 1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.

  本发明提供了一般式I的化合物：或其药学上可接受的盐，其中X，n，Y和R1在此总体上和子集中被定义。本发明的化合物是CCR2的抑制剂，因此可用于治疗各种炎症、过敏和自身免疫性疾病、障碍或病况。
• Compounds Useful as Antagonists of CCR2
  申请人：Ghosh Shomir

  公开号：US20090197884A1

  公开（公告）日：2009-08-06

  The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.

  本发明提供一般式I的化合物或其药学上可接受的盐，其中X、n、Y和R1在此概括和子集中定义。本发明的化合物是CCR2的抑制剂，因此可用于治疗各种炎症、过敏和自身免疫性疾病、紊乱或状况。
• ANTIDEPRESSANT HETEROCYCLIC COMPOUNDS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1146871A1

  公开（公告）日：2001-10-24
• EP1146871A4
  申请人：——

  公开号：EP1146871A4

  公开（公告）日：2002-04-17